$17.59 0.42 (+2.45%)
2/13/2012 4:00 PM

Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN)

CAPS Rating: 3 out of 5

A biopharmaceutical company committed to improving the lives of people with diabetes, obesity and other diseases through the discovery, development and commercialization of innovative medicines.

Recs

0
Player Avatar TMFBreakerJava (99.38) Submitted: 9/5/2008 1:04:04 AM : Outperform Start Price: $21.12 AMLN Score: -55.03

Promising results for Byetta offer the prospect of a better drug for diabetes. A potential blockbuster at a knockdown price. Buy!

Report this Post Add Comment

Featured Broker Partners


Advertisement